Published in Adv Biochem Psychopharmacol on January 01, 1980
Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox Res (2009) 1.04
Coactivation of M(1) muscarinic and alpha1 adrenergic receptors stimulates extracellular signal-regulated protein kinase and induces long-term depression at CA3-CA1 synapses in rat hippocampus. J Neurosci (2008) 1.01
A novel role for glyceraldehyde-3-phosphate dehydrogenase and monoamine oxidase B cascade in ethanol-induced cellular damage. Biol Psychiatry (2009) 0.97
The dopamine β-hydroxylase -1021C/T polymorphism is associated with the risk of Alzheimer's disease in the Epistasis Project. BMC Med Genet (2010) 0.88
Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis. Neurotox Res (2009) 0.84
Ethanol increases TIEG2-MAO B cell death cascade in the prefrontal cortex of ethanol-preferring rats. Neurotox Res (2010) 0.81
The New Inhibitor of Monoamine Oxidase, M30, has a Neuroprotective Effect Against Dexamethasone-Induced Brain Cell Apoptosis. Front Neurosci (2010) 0.81
Brain aging phenomena in migrating sockeye salmon Oncorhynchus nerka nerka. J Neural Transm (Vienna) (2005) 0.79
Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems. Neuropharmacology (2013) 0.78
The expression of KLF11 (TIEG2), a monoamine oxidase B transcriptional activator in the prefrontal cortex of human alcohol dependence. Alcohol Clin Exp Res (2013) 0.78
Chronic Social Stress and Ethanol Increase Expression of KLF11, a Cell Death Mediator, in Rat Brain. Neurotox Res (2015) 0.76
Arvid Carlsson, and the story of dopamine. Indian J Psychiatry (2010) 0.75
Binge ethanol exposure increases the Krüppel-like factor 11-monoamine oxidase (MAO) pathway in rats: Examining the use of MAO inhibitors to prevent ethanol-induced brain injury. Neuropharmacology (2016) 0.75
Ethanol induced antidepressant-like effect in the mouse forced swimming test: modulation by serotonergic system. Psychopharmacology (Berl) (2016) 0.75
Current concepts in mild cognitive impairment. Arch Neurol (2001) 18.09
Influence of social network on occurrence of dementia: a community-based longitudinal study. Lancet (2000) 7.31
A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med (1995) 4.71
A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet (1992) 4.31
Tissue receptor for cholera exotoxin: postulated structure from studies with GM1 ganglioside and related glycolipids. Infect Immun (1973) 4.08
Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol (1999) 3.62
The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med (1997) 3.49
A prospective randomised trial of internal fixation versus arthroplasty for displaced fractures of the neck of the femur. Functional outcome for 450 patients at two years. J Bone Joint Surg Br (2002) 3.40
Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol (2001) 3.19
Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology (2007) 2.72
A procedure for the quantitative isolation of brain gangliosides. Biochim Biophys Acta (1980) 2.63
Effect of antidepressant drugs on the depletion of intraneuronal brain 5-hydroxytryptamine stores caused by 4-methyl-alpha-ethyl-meta-tyramine. Eur J Pharmacol (1969) 2.61
Heritability for Alzheimer's disease: the study of dementia in Swedish twins. J Gerontol A Biol Sci Med Sci (1997) 2.59
Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol (2007) 2.47
The course of cognitive impairment in preclinical Alzheimer disease: three- and 6-year follow-up of a population-based sample. Arch Neurol (2000) 2.37
Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. Diabetes (1999) 2.36
Post-thrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost (2006) 2.32
The appropriateness of drug use in an older nondemented and demented population. J Am Geriatr Soc (2001) 2.30
Effects of some antidepressant drugs on the depletion of intraneuronal brain catecholamine stores caused by 4,alpha-dimethyl-meta-tyramine. Eur J Pharmacol (1969) 2.26
Education and dementia: what lies behind the association? Neurology (2007) 2.26
Muscle spindle activity in alternating tremor of Parkinsonism and in clonus. J Neurol Neurosurg Psychiatry (1975) 2.21
The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity. J Neural Transm Gen Sect (1993) 2.20
Low blood pressure and dementia in elderly people: the Kungsholmen project. BMJ (1996) 2.20
Interaction of cholera toxin and membrane GM1 ganglioside of small intestine. Proc Natl Acad Sci U S A (1975) 2.18
Very old women at highest risk of dementia and Alzheimer's disease: incidence data from the Kungsholmen Project, Stockholm. Neurology (1997) 2.14
Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology (2004) 2.10
Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol (1999) 2.08
An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord (2006) 2.08
Rabbit intestinal glycoprotein receptor for Escherichia coli heat-labile enterotoxin lacking affinity for cholera toxin. Infect Immun (1982) 2.08
Prevalence of Alzheimer's disease and other dementias in an elderly urban population: relationship with age, sex, and education. Neurology (1991) 2.05
Major depression in stroke patients. A 3-year longitudinal study. Stroke (1993) 2.04
Simultaneous liquid chromatographic determination of seventeen of the major monoamine neurotransmitters, precursors and metabolites. II. Assessment of human brain and cerebrospinal fluid concentrations. J Chromatogr (1987) 2.04
Vitamin B(12) and folate in relation to the development of Alzheimer's disease. Neurology (2001) 2.04
Scanning electron microscopic study of virulent and avirulent colonies of Neisseria gonorrhoeae. Infect Immun (1975) 2.03
Relationship between prophylactic effect of lithium therapy and family history of affective disorders. Biol Psychiatry (1997) 2.03
The effects of probiotics on barrier function and mucosal pouch microbiota during maintenance treatment for severe pouchitis in patients with ulcerative colitis. Aliment Pharmacol Ther (2013) 2.01
Volume and number of neurons of the human hippocampal formation in normal aging and Alzheimer's disease. J Comp Neurol (1997) 1.99
Acute confusional states in elderly patients treated for femoral neck fracture. J Am Geriatr Soc (1988) 1.95
Krabbe disease: a galactosylsphingosine (psychosine) lipidosis. J Lipid Res (1980) 1.93
Interactions between glutamatergic and monoaminergic systems within the basal ganglia--implications for schizophrenia and Parkinson's disease. Trends Neurosci (1990) 1.91
Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci U S A (1994) 1.91
Fixation and inactivation of cholera toxin by GM1 ganglioside. Scand J Infect Dis (1973) 1.90
Power of selective genotyping in genetic association analyses of quantitative traits. Behav Genet (2000) 1.89
Defective brain microtubule assembly in Alzheimer's disease. Lancet (1986) 1.89
Receptor-specific large-scale purification of cholera toxin on silica beads derivatized with lysoGM1 ganglioside. Eur J Biochem (1981) 1.89
Diabetes, Alzheimer disease, and vascular dementia: a population-based neuropathologic study. Neurology (2010) 1.88
Distribution and fatty acid composition of phosphoglycerides in normal human brain. J Lipid Res (1968) 1.83
Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry (1998) 1.83
Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology (2007) 1.81
Brain regions associated with episodic retrieval in normal aging and Alzheimer's disease. Neurology (1999) 1.78
White-matter lesions on CT in Alzheimer patients: relation to clinical symptomatology and vascular factors. Acta Neurol Scand (1991) 1.77
Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J Intern Med (2014) 1.75
Accumulation of glucosylceramide and glucosylsphingosine (psychosine) in cerebrum and cerebellum in infantile and juvenile Gaucher disease. J Neurochem (1982) 1.72
Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br J Psychiatry (1979) 1.71
Distribution of different fiber types in human skeletal muscles: effects of aging studied in whole muscle cross sections. Muscle Nerve (1983) 1.70
The occurrence of depressive symptoms in the preclinical phase of AD: a population-based study. Neurology (1999) 1.67
Monoclonal antibodies against gastrointestinal tumour-associated antigens isolated as monosialogangliosides. Int Arch Allergy Appl Immunol (1983) 1.67
Homocysteine and holotranscobalamin and the risk of Alzheimer disease: a longitudinal study. Neurology (2010) 1.67
Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport (2001) 1.63
Ultrastructural localization of cell membrane GM1 ganglioside by cholera toxin. Proc Natl Acad Sci U S A (1977) 1.61
APOE influences on neuropsychological function after mild head injury: within-person comparisons. Neurology (2004) 1.58
The impact of chronic multimorbidity and disability on functional decline and survival in elderly persons. A community-based, longitudinal study. J Intern Med (2009) 1.57
Modification of sympathetic function. Pharmacological depletion of catecholamine stores. Pharmacol Rev (1966) 1.56
Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord (1998) 1.55
Underdiagnosis and poor documentation of acute confusional states in elderly hip fracture patients. J Am Geriatr Soc (1991) 1.55
Occurrence of dementia in advanced age: the study design of the Kungsholmen Project. Neuroepidemiology (1992) 1.54
Heart failure and Alzheimer's disease. J Intern Med (2014) 1.54
Institutionalization in the elderly: the role of chronic diseases and dementia. Cross-sectional and longitudinal data from a population-based study. J Clin Epidemiol (2001) 1.54
Movement patterns of the C-stem femoral component: an RSA study of 33 primary total hip arthroplasties followed for two years. J Bone Joint Surg Br (2005) 1.53
Costs of dementia and dementia care: a review. Int J Geriatr Psychiatry (1997) 1.52
Dementia is the major cause of functional dependence in the elderly: 3-year follow-up data from a population-based study. Am J Public Health (1998) 1.51
A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia. Neurology (1998) 1.50
Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med (1993) 1.50
Aging and the occurrence of dementia: findings from a population-based cohort with a large sample of nonagenarians. Arch Neurol (1999) 1.50
Biochemical and histochemical studies on the effects of imipramine-like drugs and (+)-amphetamine on central and peripheral catecholamine neurons. Acta Physiol Scand (1967) 1.49
A schizophrenia-susceptibility locus at 6q25, in one of the world's largest reported pedigrees. Am J Hum Genet (2001) 1.49
The role of amyloid beta-protein in Alzheimer's disease. Lancet (1992) 1.49
Quantitative electroencephalography in mild cognitive impairment: longitudinal changes and possible prediction of Alzheimer's disease. Neurobiol Aging (2000) 1.49
Postoperative confusion after anesthesia in elderly patients with femoral neck fractures. Anesth Analg (1987) 1.48
Clinical trials in mild cognitive impairment: lessons for the future. J Neurol Neurosurg Psychiatry (2005) 1.47
Continuous distal migration and internal rotation of the C-stem prosthesis without any adverse clinical effects: an RSA study of 33 primary total hip arthroplasties followed for up to ten years. Bone Joint J (2014) 1.45
Specific gangliosides function as host cell receptors for Sendai virus. Proc Natl Acad Sci U S A (1981) 1.45
Preclinical symptoms of major depression in very old age: a prospective longitudinal study. Am J Psychiatry (1998) 1.43
Absence of hexosaminidase A and B in a normal adult. N Engl J Med (1975) 1.43
Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biol Psychiatry (2000) 1.43
Treatment of Alzheimer disease with tacrine: a cost-analysis model. Alzheimer Dis Assoc Disord (1997) 1.42
Computerised tomography in severe methanol intoxication. Br Med J (1978) 1.42
Growth pattern and cell division in Neisseria gonorrhoeae. J Bacteriol (1977) 1.40
PMP22 Thr(118)Met: recessive CMT1 mutation or polymorphism? Nat Genet (1997) 1.39
The influence of education on clinically diagnosed dementia incidence and mortality data from the Kungsholmen Project. Arch Neurol (2001) 1.38
Human brain contains high levels of heteroplasmy in the noncoding regions of mitochondrial DNA. Proc Natl Acad Sci U S A (1996) 1.38
Screening for neurotrophic disturbances in amyotrophic lateral sclerosis. Acta Neurol Scand (1989) 1.38
Altered brain white matter integrity in healthy carriers of the APOE epsilon4 allele: a risk for AD? Neurology (2006) 1.38
Mortality from dementia in advanced age: a 5-year follow-up study of incident dementia cases. J Clin Epidemiol (1999) 1.38
Elevated cortical zinc in Alzheimer disease. Neurology (2006) 1.38
Membrane lipids, selectively diminished in Alzheimer brains, suggest synapse loss as a primary event in early-onset form (type I) and demyelination in late-onset form (type II). J Neurochem (1994) 1.38
Levels of alpha- and beta-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients. Neurosci Lett (2000) 1.37
[More accurate diagnosis could identify patients suitable for tacrine therapy]. Lakartidningen (1996) 1.37